Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Jinling Hospital, China
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06818305CT.gov Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT | — | Terminated | — | — | — |
NCT04143581CT.gov SGLT2 Inhibitors in Glomerular Hyperfiltration | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Kidney Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Empagliflozin (this asset) | Jinling Hospital, China | P2 | CCC · 53 |
| Sodium Ferric Gluconate | Watson Pharmaceuticals | P4 | BBB |
| Iron(Ii) Sulphate (1:1), Heptahydrate | Watson Pharmaceuticals | P4 | BBB |
| Semaglutide | Institute of Liver and Biliary Sciences, India | P4 | BBB |
| Clopidogrel | Hospital Alemão Oswaldo Cruz | P4 | BB |
| Aspirin | Hospital Alemão Oswaldo Cruz | P4 | BB |
| Retatrutide | Eli Lilly and Company | P3 | BB |
| Simethicone | Alfredo Di Leo | P4 | BB |
| Cilostazol | Kyunghee University Medical Center | P4 | BB |
+42 more in the Chronic Kidney Disease cohort
Other indications for Empagliflozin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | BBB · 74 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BBB · 73 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Empagliflozin in Chronic Kidney Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/empagliflozin-chronic-kidney-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →